Prelude Capital Management’s Dynavax Technologies DVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-236,329
Closed -$3.63M 1305
2025
Q4
$3.63M Buy
+236,329
New +$2.6M 0.27% 73
2025
Q2
Sell
-17,964
Closed -$233K 1090
2025
Q1
$233K Buy
+17,964
New +$238K 0.02% 837
2020
Q1
Sell
-442
Closed -$3K 1558
2019
Q4
$3K Sell
442
-44
-9% -$235 ﹤0.01% 1803
2019
Q3
$2K Buy
+486
New +$1.88K ﹤0.01% 1616
2019
Q2
Sell
-567
Closed -$4K 1770
2019
Q1
$4K Buy
567
+275
+94% +$2.69K ﹤0.01% 1649
2018
Q4
$3K Buy
+292
New +$3.23K ﹤0.01% 1667
2017
Q4
Sell
-2,500
Closed -$54K 1433
2017
Q3
$54K Buy
+2,500
New +$39.6K ﹤0.01% 1073
2016
Q1
Sell
-10,805
Closed -$261K 1319
2015
Q4
$261K Sell
10,805
-2,200
-17% -$55.1K 0.04% 456
2015
Q3
$319K Buy
+13,005
New +$368K 0.05% 409

Other funds holding DVAX

Prelude Capital Management's DVAX Position: Q1 2026 in Review

Prelude Capital Management sold out of Dynavax Technologies (DVAX) in Q1 2026, closing a stake of 236,329 shares — an estimated $3.63M sold.

Prelude Capital Management first reported a position in DVAX in Q3 2015 and held it in 9 quarters. The position peaked at $3.63M in Q4 2025. 1 fund tracked by Wall St. Rank holds DVAX as of Q1 2026.

  • Prelude Capital Management reported no remaining Dynavax Technologies position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 236,329 Dynavax Technologies shares in Q1 2026, an estimated $3.63M.
  • Prelude Capital Management first reported a position in Dynavax Technologies in Q3 2015 and held it in 9 quarters.
  • Prelude Capital Management's Dynavax Technologies position peaked at $3.63M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Dynavax Technologies as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.